Literature DB >> 3565812

Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine.

F Donati, S M McCarroll, C Antzaka, D McCready, D R Bevan.   

Abstract

To determine the potencies of neostigmine, pyridostigmine, and edrophonium in reversing pancuronium and d-tubocurarine blockade, dose-response curves were established for first twitch height recovery and train-of-four ratio. One hundred and twenty ASA physical status I or II patients scheduled for elective surgery received either 0.06 mg/kg pancuronium or 0.36 mg/kg d-tubocurarine during a thiopental-nitrous oxide-enflurane anesthetic. Train-of-four stimulation was applied every 12 s, and the force of contraction of the adductor pollicis muscle was recorded. When first twitch height had recovered spontaneously to 10% of its initial value, neostigmine (0.005, 0.01, 0.02 or 0.05 mg/kg), pyridostigmine (0.02, 0.04, 0.1, or 0.2 mg/kg), or edrophonium (0.1, 0.2, 0.4 or 1 mg/kg) was injected by random allocation. Recovery was measured 10 min after the injection of the antagonist. First twitch ED50's were 0.013, 0.085, and 0.17 mg/kg after pancuronium, and 0.017, 0.11, and 0.27 mg/kg after d-tubocurarine, for neostigmine, pyridostigmine, and edrophonium, respectively. The ED50 for pyridostigmine and edrophonium obtained after d-tubocurarine was significantly larger (P less than 0.05) than that after pancuronium. The train-of-four dose-response curves were significantly flatter for edrophonium than for the other two agents, indicating a greater ability of edrophonium to antagonize fade at low doses. It is concluded that the potency of reversal agents may be different for different relaxants, and that potency ratios might depend upon the end-point chosen as full neuromuscular recovery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3565812     DOI: 10.1097/00000542-198704000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

Review 1.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  "Priming" with neostigmine: failure to accelerate reversal of single twitch and train-of-four responses.

Authors:  F Donati; C E Smith; S Wiesel; D R Bevan
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

3.  The current status of edrophonium: have we come "full circle"?

Authors:  A F Kopman
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

4.  Edrophonium priming for antagonism of atracurium neuromuscular blockade.

Authors:  J E Szalados; F Donati; D R Bevan
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

5.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

6.  Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children.

Authors:  J C Bevan; J P Purday; E J Reimer; D R Bevan
Journal:  Can J Anaesth       Date:  1994-11       Impact factor: 5.063

7.  Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients.

Authors:  Shilpa Bhimasen Joshi; Ks Vasudeva Upadhyaya; M Manjuladevi
Journal:  Indian J Anaesth       Date:  2015-03

8.  Effects of different sugammadex doses on the train of four ratio recovery progression during rocuronium induced neuromuscular blockade in the rat phrenic nerve hemidiaphragm.

Authors:  Yong Beom Kim; Jae-Moon Choi; Young-Jin Chang; Hey-Ran Choi; Junyong In; Hong-Seuk Yang
Journal:  Korean J Anesthesiol       Date:  2019-10-17

9.  Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey.

Authors:  Jin Sun Kim; Jung Woo Han; Jae Ho Lee; Jae Moon Choi; Ha Jung Kim; Tae-Yun Sung; Yong Beom Kim; Yong Seop Shin; Hong Seuk Yang
Journal:  Anesth Pain Med (Seoul)       Date:  2019-10-31

10.  Effects of hydrocortisone-presensitized sugammadex on recovery from neuromuscular blockade induced by rocuronium: a rodent in vivo study.

Authors:  Hey-Ran Choi; Hong-Seuk Yang; Jae-Moon Choi; Chungon Park; Junyong In; Yong Beom Kim
Journal:  Anesth Pain Med (Seoul)       Date:  2022-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.